Abstract Number: 439 • 2012 ACR/ARHP Annual Meeting
Interaction of Antibodies Against Citrullinated Peptides with HLA Shared Epitope, PTPN22 1858T Variant, and Smoking in Individuals Prior to and After the Development of Rheumatoid Arthritis
Background/Purpose: The presence of antibodies against cyclic citrullinated peptides (ACPA) has been demonstrated to precede the development of rheumatoid arthritis (RA) by several years. The…Abstract Number: 440 • 2012 ACR/ARHP Annual Meeting
Effects of Fetal Microchimerisms On Disease Onset and Severity in Women with Rheumatoid Arthritis and Systemic Lupus Erythematosus
Background/Purpose: The major source of naturally acquired microchimerisms (MC) is the transplacental traffic of fetal cells between a mother and the fetus during pregnancy. Fetal…Abstract Number: 441 • 2012 ACR/ARHP Annual Meeting
Performance of Anti-Cyclic Citrullinated Peptide Assays Differs in Healthy Subjects At Elevated Risk for Future Rheumatoid Arthritis and Subjects with Established Disease
Background/Purpose: The 2010 ACR/EULAR RA criteria include autoantibodies to cyclic citrullinated peptides (CCP) that are highly specific for RA in the setting of inflammatory arthritis…Abstract Number: 442 • 2012 ACR/ARHP Annual Meeting
Joint Effects of Known Genetic Markers of Rheumatoid Arthritis Risk and 25-Hydroxyvitamin D On Rheumatoid Arthritis Risk
Background/Purpose: Rheumatoid arthritis (RA) is a complex disease with both genetic and environmental risk factors. A number of susceptibility genes have been identified. Past studies…Abstract Number: 443 • 2012 ACR/ARHP Annual Meeting
Secreted Frizzled-Related Protein 5 Exerts the Anti-Inflammatory Role in Rheumatoid Arthritis Via Down-Regulation of c-Jun N-Terminal Kinase
Background/Purpose: Secreted frizzled-related protein 5 (Sfrp5) is a novel adipokine that has beneficial effects on metabolic dysfunction by controlling inflammatory cells within adipose tissue. Sfrp5…Abstract Number: 444 • 2012 ACR/ARHP Annual Meeting
Tocilizumab Improves Bone Mineral Density Compared with Abatacept in Patients with TNF Blockers-Resistant Active Rheumatoid Arthritis. an Open Label Randomized Controlled Trial
Background/Purpose: To compare the effect of tocilizumab(TCZ) plus methotrexate (MTX), with the effect of abatacept(ABT) plus MTX on bone mineral density(BMD) in TNF blockers resistant…Abstract Number: 445 • 2012 ACR/ARHP Annual Meeting
Combination of Intra-Articular Steroid Injection and Infliximab More Effective Than Infliximab in Rapid Radiographic Progression Patients with Rheumatoid Arthritis: A Randomized, Open Label, x Ray Reader Blinded Study
Background/Purpose: Treatment of rheumatoid arthritis (RA) should aim at full remission. However, recent publications described rapid radiographic progression (RRP) existed despite initial biologics and methotrexate…Abstract Number: 446 • 2012 ACR/ARHP Annual Meeting
Clinical Remission and Rate of Relapse After Tocilizumab Withdrawal in Rheumatoid Arthritis Patients
Background/Purpose: Although there is much discussion regarding when to initiate a biological agent in rheumatoid arthritis (RA) patients, data on when to stop these agents…Abstract Number: 447 • 2012 ACR/ARHP Annual Meeting
Long-Term Safety and Efficacy of Tabalumab, an Anti-B-Cell Activating Factor Monoclonal Antibody, in Patients with Rheumatoid Arthritis: A 52-Week, Open-Label Extension Study
Background/Purpose: Tabalumab, a monoclonal antibody that neutralizes membrane-bound and soluble B cell activating factor (BAFF), has been shown to reduce rheumatoid arthritis (RA) signs and…Abstract Number: 448 • 2012 ACR/ARHP Annual Meeting
Sustained and Cumulated Response Over Time in Rheumatoid Arthritis Patients Treated with Rituximab After Initial Failure of Anti Tumor Necrosis Factor Agents
Background/Purpose: Although anti-TNF therapies moved forward the treatment of rheumatoid arthritis (RA), failure of the first anti-TNF medication is not uncommon. Many times modifying dosage/frequency…Abstract Number: 449 • 2012 ACR/ARHP Annual Meeting
Rituximab After First Anti Tumor Necrosis Factor Failure Is More Efficient with High Impact in Reducing Time and Costs to Achieve Superior Rates of Low Disease Activity and Remission
Background/Purpose: Significant steps were done in creating new medications for treatment of rheumatoid arthritis (RA). As RA seriously affects the patients’ quality of life, the…Abstract Number: 410 • 2012 ACR/ARHP Annual Meeting
Early Growth Response-1 (EGR-1) Controls Synoviocyte Apoptosis, and Its Expression Is Regulated by the Direct Binding of Fibroblast Growth Factor-1 (FGF1) or Insulin-Like Growth Factor-1 (IGF1) to Integrin αvβ3
Background/Purpose: Growth factors such as fibroblast growth factor (FGF) and insulin-like growth factor (IGF) are of interest in the initiation and development of rheumatoid arthritis…Abstract Number: 411 • 2012 ACR/ARHP Annual Meeting
Early Menopause, Smoking and Circulating Antibodies Against Citrullinated Peptides in the Pre-Clinical Phase of Rheumatoid Arthritis
Background/Purpose: Previous studies indicate that anti-citrullinated peptide antibodies (ACPAs) may be detected in individuals who later develop rheumatoid arthritis (RA) years before onset, and that…Abstract Number: 412 • 2012 ACR/ARHP Annual Meeting
Single Nucleotide Polymorphisms within the HLA-DRB1 Gene in Relation to Antibodies Against Citrullinated Peptides in Individuals Prior to the Development of Rheumatoid Arthritis
Background/Purpose: Multiplex analysis has demonstrated the presence of several antibodies against cyclic citrullinated peptides (ACPA) preceding the development of rheumatoid arthritis (RA) by several years.…Abstract Number: 413 • 2012 ACR/ARHP Annual Meeting
α(1,2)-Linked Fucosylated Cytokines Are Upregulated in Rheumatoid Arthritis
Background/Purpose: Glycosylation is a common post-translational modification of proteins in eukaryotes. Fucosylated glycans are synthesized by fucosyltransferases (futs). We previously reported that sialyl Lewisx, synthesized…